Royalty Pharma snaps up interest in Tecfidera; Bayer's Algeta buy wins nod; FDA slaps Dara for misleading ad;

@FiercePharma: Rebel Teva shareholder throws his support to presumptive CEO Vigodman. Story | Follow @FiercePharma

@EricPFierce: There were fewer NDA's approved by the FDA in 2013, but there were some significant ones. Report | Follow @EricPFierce

@CarlyHFierce: Bayer's hot-selling Eylea runs into a roadblock in its home market. More | Follow @CarlyHFierce

> Royalty Pharma bought an indirect interest in sales of Biogen Idec's ($BIIB) new multiple sclerosis drug Tecfidera as part of a $510 million deal for earn-outs due to former Fumapharm shareholders. Report

> Bayer's buyout of the biotech company Algeta won regulatory approval from German competition watchdogs. Report

> The FDA cited Raleigh, NC-based Dara BioSciences for running misleading advertising for its treatment for breast cancer patients, Soltamox. Report

> GlaxoSmithKline ($GSK) has formally filed for Indian approval to increase its stake in its domestic subsidiary to 75% from 50.67%. Report

> The Spanish blood products company Grifols inked a $1.5 billion bridge loan to help pay for its buyout of Novartis' ($NVS) blood diagnostics business. Report

> Novartis' unit in India plans to consolidate operations scattered around Hyderabad into one 8,000-employee facility, Indian media reports. Report

Medical Device News

@FierceMedDev: TrovaGene recruits US Oncology Research for a pancreatic cancer Dx trial. News | Follow @FierceMedDev

@MichaelGFierce: Gene delivery method 'hijacks' tumor blood vessels. More | Follow @MichaelGFierce

> Medtronic gives it another go with atrial fibrillation device. News

> Topera snags FDA OK for latest heart-mapping tech. Story

> Quest beefs up its Indian presence as stateside sales sag. Piece

> Thermo nears Life Tech merger with $1.1B sale to GE. Article

Biotech News

@FierceBiotech: FierceBiotech's first special report of 2014: An ominous trend resurfaces as new drug approvals plunge in 2013. Report | Follow @FierceBiotech

@JohnCFierce: GE beefs up life sciences division with $1.06B Thermo Fisher deal. Story | Follow @JohnCFierce

@DamianFierce: "Moon Shots" = excellent naming. MD Anderson teams up with Pfizer to advance cancer immunotherapy. Release | Follow @DamianFierce

@EmilyMFierce: 6 U.S. institutions receive $540M in cancer research funds. Item | Follow @EmilyMFierce

> J&J gambles $12.5M in rare Big Pharma bet on a stem cell therapy. More

> Fast-growing Aratana beefs up pet drug pipeline with a $44M buyout. Piece

> Analysts score the winners in the FDA's new 'breakthrough' category. News

CRO News

> Cyprotex bags a U.S. CRO for up to $5.1M. Report

> DaVita ups its CRO weight with latest partnership. News

> Sanofi stops short of baring it all with clinical trial transparency pledge. More

> Can Parexel regain some confidence after a major slip? Article

> India further tightens clinical trial rules as demand plummets. Story

> Report: Big or small, CROs need good relationships to thrive. Item

Biotech IT News

> Google VC commits to $15M round to advance DNAnexus' data hub ambitions. Report

> NIH puts improved data handling at top of BRAIN Initiative wish list. Story

> FDA plans raft of IT guidance documents to further GDUFA goals. News

> Days after Big Pharma trumpets data sharing plans, U.K. politicians push for more transparency. Article

> Spun out of George Church's lab, Curoverse gets $1.5M for open-source bio Big Data. More

> IMS Health files for IPO after making string of tech takeovers. Item

And Finally... Acupuncture--real and fake--helped ease menopausal symptoms in women treated with aromatase inhibitors for breast cancer. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.